Reckitt CEO's $17B Predicament Post author:Sam Post published:December 26, 2017 Post category:BioPharma 2018 is the year for Rakesh Kapoor to show he’s worth it. Source: BioSpace You Might Also Like Vivasure Medical Enrolls First Patient In Frontier IV Clinical Trial October 12, 2017 3 Hottest Areas of Drug Development to Keep an Eye on in 2018 December 19, 2017 DURECT Stock Plunges as Pain Med Fails Phase III October 19, 2017
